Ptc Therapeutics, Inc. stock: filings, catalysts and timeline
Sign in to follow
FundamentalsWhat is this?HideNot scored — outside AIR's $300M–$20B fundamentals band
How the business is doing on its own reported US-GAAP numbers — growth, margins, cash generation, balance-sheet strength, capital efficiency and dilution — compared with sector peers.
Source: SEC XBRL financial statements.
ValueWhat is this?HideWatch
How the shares are priced against sector peers, against the company's own recent history, and against a simple cash-flow estimate, using the filing numbers and the current price. AIR shows this as a band, never as a target price.
Source: SEC XBRL financial statements and end-of-day prices.
News flowWhat is this?HideBalanced
What the company has documented recently: material 8-K events (contracts, deals, results, leadership changes) and FDA approvals, weighted by recency and type. A language model's reading of each 8-K helps classify whether it is positive or negative. Filings, not press or social media.
Source: SEC EDGAR 8-K filings and FDA approvals.
MomentumWhat is this?HideWatch
The longer-term market read: the trend in end-of-day prices, strength against the market and the sector, and trading volume over roughly the past three to twelve months. It is shown, never used to rank the Shortlist.
Source: End-of-day prices.
SafetyWhat is this?HideStrong
The risk side: leverage, liquidity, cash runway, dilution, revenue and margin swings, company size and pre-commercial status, negative 8-K events (including legal and regulatory ones), and share-price drawdown and volatility. Higher means fewer of those risk markers.
Source: SEC XBRL financial statements, SEC EDGAR 8-K filings and end-of-day prices.
Discovery Gap: Very high (55/100) · Gap confidence 42/100
Documented progress is running well ahead of market attention.
Low is the most common level — the cut-offs are fixed, and levels can shift as scores refresh.
What is this?Hide
How far documented progress (News flow) runs ahead of market attention. Attention is measured from institutional holdings reported to the SEC, trading volume, price behaviour and how richly the shares are valued — not from social media or analyst ratings.
Source: SEC EDGAR filings (8-K and 13F), FDA approvals and end-of-day prices.
How levels work. The levels use fixed cut-offs, but market attention is ranked against the other ~1,800 companies AIR covers that day (valuation against the same sector). Documented progress counts filings from the past 18 months, newer ones weighing more; attention uses the latest quarter of institutional holdings, the last three to six months of trading, and six to twelve months of price behaviour. Many companies show a Low Gap or none at all — a gap needs filings that read more positively than neutral. A level can change from one day to the next as scores refresh and the other companies move.
Gap confidenceWhat is this?HideModerate 42/100How fully AIR could measure this Gap.
How fully AIR could measure both sides of the Discovery Gap: the documented progress (News flow) and market attention (Recognition). It takes the weaker of the two, and reads zero when either side has no measurement. It describes the data, not the company.
Evidence strengthWhat is this?HideStrong 62/100Support behind the full AIR read, not only the Gap.
How much data stands behind the whole AIR read — all five perspectives, not just the Discovery Gap. Each perspective reports how complete its inputs are, and these are combined in the same proportions as the AIR Score; a perspective AIR could not score adds nothing, so missing data lowers this figure. It describes the data, not the company.
This month at a glance
Capital returns
Latest buyback
Buyback approved · Approved a $500 million share buyback.
Filed 3 Nov 2026 · As stated in the filing →
Evidence timeline
- Expected
Fri 19 Feb · expected 10-K
Last year filed 19 Feb 2026.
Fri 7 May · expected 10-Q
Last year filed 7 May 2026.
- Filed
Tue 3 Nov · 8-K
8-K · Item 8.01 — Other events
Recognition: Watch 40 → Balanced 45Value: Watch 36 → Watch 33Gap Very high · 60 → Very high · 55The shares became dearer on AIR's value read.
The gap narrowed — attention is catching up.
The price trend strengthened.
- Buyback approvedApproved a $500 million share buyback. As stated in the filing →
Thu 29 Oct · 8-K
8-K · Item 2.02 — Results of operations
PTC Therapeutics reported Q3 2026 revenue of $358M (product revenue $276M), beating expectations. Full-year guidance raised to $1.29–$1.32B total revenue and $960–$990M product revenue. Sephience momentum strong at $182M Q3 revenue with 2,000+ active patients globally.
Value: Balanced 45 → Watch 36Gap Very high · 51 → Very high · 59The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
Thu 29 Oct · 10-Q
Quarterly report (10-Q), period ending 30 Sep 2026
Value: Balanced 45 → Watch 36Gap Very high · 51 → Very high · 59The shares became dearer on AIR's value read.
Progress is running ahead of attention.
The price trend strengthened.
Mon 21 Sep · 8-K
8-K · Item 8.01 — Other events
Recognition: Balanced 52 → Watch 43Market attention has faded.
The price trend weakened.
Fri 28 Aug · 8-K
Thu 13 Aug · 8-K
Thu 30 Jul · 8-K
Thu 30 Jul · 10-Q
Quarterly report (10-Q), period ending 29 Jul 2026
Thu 18 Jun · 8-K
Tue 16 Jun · 8-K
Tue 9 Jun · 8-K
Fri 5 Jun · 8-K
Thu 7 May · 8-K
Thu 7 May · 10-Q
Quarterly report (10-Q), period ending 5 May 2026
Tue 28 Apr · 8-K
Wed 25 Mar · 8-K
Thu 19 Feb · 10-K
Annual report (10-K), FY2026
Thu 19 Feb · 8-K
Thu 12 Feb · 8-K
Mon 12 Jan · 8-K
Mon 29 Dec · 8-K
Tue 4 Nov · 8-K
Tue 4 Nov · 10-Q
Quarterly report (10-Q), period ending 3 Nov 2025
Solid dots: a filing AIR classified as material. Grey: routine. Hollow: expected, from last year's dates — not a forecast.
Ask AIR
What would change our view
Research, not tips. No buy/sell recommendations, no price forecasts. Every score is derived from public filings and market data — figures round to whole numbers and refresh each trading day.